Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analytical approach

被引：0
|
作者：
Grossi, Francesco
Belvedere, Ornella
Defferrari, Carlotta
Rosetti, Francesco
Vinante, Orazio
Pappagallo, Giovanni
机构：
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Udine, I-33100 Udine, Italy
[3] Osped PF Calvi, Noale, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [1] Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analytical approach
    Grossi, Francesco
    Defferrari, Carlotta
    Vinante, Orazio
    Rosetti, Francesco
    Pronzato, Paolo
    Pappagallo, Giovanni
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S339 - S339
  • [2] Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analytical approach
    Grossi, F.
    Belvedere, O.
    Defferrari, C.
    Vinante, O.
    Pappagallo, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI25 - XI25
  • [3] Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
    Grossi, Francesco
    Aita, Marianna
    Defferrari, Carlotta
    Rosetti, Francesco
    Brianti, Annalisa
    Fasola, Gianpiero
    Vinante, Orazio
    Pronzato, Paolo
    Pappagallo, Giovanni
    ONCOLOGIST, 2009, 14 (05): : 497 - 510
  • [4] Impact of gemcitabine (G) on the activity of first-line chemotherapy in non-small cell lung cancer (NSCLC): A meta-analysis.
    Pappagallo, G. L.
    Belvedere, O.
    Vinante, O.
    Grossi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 398S - 398S
  • [5] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [6] Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Gronberg, B. H.
    Lund-Iversen, M.
    Strom, E. H.
    Brustugun, O. T.
    Scott, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [8] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
    Andric, Z. G.
    Galffy, G.
    Cobo Dols, M.
    Szima, B.
    Stojanovic, G.
    Petrovic, M. D.
    Felip Font, E.
    Vicente Baz, D.
    Ponce Aix, S.
    Juan-Vidal, O.
    Tehenes, S.
    Szalai, Z.
    Losonczy, G.
    Calles Blanco, A.
    Bernabe, R.
    Duecker, K.
    Zhou, D.
    Schroeder, A.
    Guezel, G.
    Ciardiello, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
  • [9] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
  • [10] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gaspar, E.
    Firvida, J.
    Amenedo, M.
    Orts, D.
    Salgado, M.
    LLorca, C.
    Ramos, M.
    Perez, E.
    Cervera, J.
    Abal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345